StockData
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) stock

TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$4.00−0.06 (-1.48%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Earnings

Taysha Gene Therapies's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 18, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.10
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Taysha Gene Therapies's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 18, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open––-$0.10Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026during market hours––-$0.13Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open––-$0.12Release
Q4 FY2025ended Dec 31, 2025Mar 19, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025before the open–––Release
Q1 FY2025ended Mar 31, 2025May 15, 2025before the open$2.30M-32.5%-$0.08Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024before the open$1.11M-53.6%-$0.09Release
Q1 FY2024ended Mar 31, 2024May 14, 2024during market hours$3.41M-27.4%-$0.10Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Taysha Gene Therapies has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Taysha Gene Therapies puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Taysha Gene Therapies filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. News
  5. Update
  6. Update
  7. Results
  8. Results
  9. Results
  10. News
  11. News
  12. News
  13. Results
  14. News
  15. News

See a number that looks wrong?